STERIS (NYSE:STE) Updates FY25 Earnings Guidance

STERIS (NYSE:STE) updated its FY25 earnings guidance on Wednesday. The company provided earnings per share (EPS) guidance of $9.05-$9.25 for the period, compared to the consensus estimate of $9.16. STERIS also updated its FY 2025 guidance to 9.050-9.250 EPS.

STERIS Trading Up 0.0 %

NYSE:STE traded up $0.08 on Wednesday, hitting $227.52. 1,402,169 shares of the stock were exchanged, compared to its average volume of 483,986. The company has a debt-to-equity ratio of 0.35, a quick ratio of 1.49 and a current ratio of 2.33. STERIS has a 52 week low of $195.47 and a 52 week high of $248.24. The stock has a market capitalization of $22.44 billion, a price-to-earnings ratio of 56.44 and a beta of 0.85. The company’s 50-day moving average price is $233.36 and its 200 day moving average price is $227.60.

STERIS (NYSE:STE) last posted its quarterly earnings results on Tuesday, August 6th. The medical equipment provider reported $2.14 earnings per share for the quarter, topping analysts’ consensus estimates of $1.98 by $0.16. STERIS had a net margin of 7.36% and a return on equity of 13.85%. The business had revenue of $1.28 billion during the quarter, compared to the consensus estimate of $1.27 billion. During the same period in the previous year, the firm posted $2.00 earnings per share. STERIS’s revenue for the quarter was down .4% compared to the same quarter last year. On average, equities research analysts forecast that STERIS will post 9.02 earnings per share for the current year.

STERIS Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Thursday, December 19th. Shareholders of record on Tuesday, November 19th will be given a dividend of $0.57 per share. This represents a $2.28 annualized dividend and a dividend yield of 1.00%. The ex-dividend date of this dividend is Tuesday, November 19th. STERIS’s payout ratio is 56.58%.

Wall Street Analysts Forecast Growth

A number of research firms recently commented on STE. Stephens reiterated an “overweight” rating and issued a $260.00 price objective on shares of STERIS in a report on Wednesday, August 7th. Needham & Company LLC reiterated a “hold” rating on shares of STERIS in a research report on Thursday, August 8th. Piper Sandler upgraded shares of STERIS from a “neutral” rating to an “overweight” rating and boosted their price objective for the company from $230.00 to $260.00 in a report on Thursday, October 24th. KeyCorp lifted their price target on shares of STERIS from $255.00 to $265.00 and gave the stock an “overweight” rating in a research report on Tuesday, September 3rd. Finally, StockNews.com cut shares of STERIS from a “strong-buy” rating to a “buy” rating in a research report on Tuesday, October 29th. Two analysts have rated the stock with a hold rating and five have given a buy rating to the company. Based on data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $253.00.

Insider Activity

In other news, Director Christopher S. Holland sold 473 shares of the stock in a transaction dated Thursday, August 8th. The shares were sold at an average price of $239.68, for a total transaction of $113,368.64. Following the completion of the transaction, the director now directly owns 582 shares in the company, valued at $139,493.76. This represents a 0.00 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. In other STERIS news, CFO Michael J. Tokich sold 23,332 shares of the stock in a transaction on Tuesday, September 10th. The shares were sold at an average price of $247.00, for a total value of $5,763,004.00. Following the completion of the sale, the chief financial officer now owns 42,930 shares in the company, valued at $10,603,710. This trade represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available through this link. Also, Director Christopher S. Holland sold 473 shares of the company’s stock in a transaction dated Thursday, August 8th. The shares were sold at an average price of $239.68, for a total transaction of $113,368.64. Following the completion of the sale, the director now directly owns 582 shares in the company, valued at approximately $139,493.76. The trade was a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Corporate insiders own 1.14% of the company’s stock.

STERIS Company Profile

STERIS plc provides infection prevention products and services worldwide. It operates through four segments: Healthcare, Applied Sterilization Technologies, Life Sciences, and Dental. The Healthcare segment offers cleaning chemistries and sterility assurance products; automated endoscope reprocessing system and tracking products; endoscopy accessories, washers, sterilizers, and other pieces of capital equipment for the operation of a sterile processing department; and equipment used directly in the operating room, including surgical tables, lights, and connectivity solutions, as well as equipment management services.